Loco-regional immunotherapy with recombinant interleukin-2 and adherent lymphokine-activated killer cells (A-LAK) in recurrent glioblastoma patients. (Q55481786)

From Wikidata

Jump to navigation Jump to search

scientific article published in September 1994

Language	Label	Description	Also known as
English	Loco-regional immunotherapy with recombinant interleukin-2 and adherent lymphokine-activated killer cells (A-LAK) in recurrent glioblastoma patients.	scientific article published in September 1994

Statements

scholarly article

1 reference

Europe PubMed Central

12 July 2018

http://europepmc.org/abstract/MED/7923250

Loco-regional immunotherapy with recombinant interleukin-2 and adherent lymphokine-activated killer cells (A-LAK) in recurrent glioblastoma patients. (English)

1 reference

Europe PubMed Central

12 July 2018

http://europepmc.org/abstract/MED/7923250

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Licia Rivoltini

4

1 reference

Europe PubMed Central

12 July 2018

http://europepmc.org/abstract/MED/7923250

author name string

A Boiardi

1

1 reference

Europe PubMed Central

12 July 2018

http://europepmc.org/abstract/MED/7923250

A Silvani

2

1 reference

Europe PubMed Central

12 July 2018

http://europepmc.org/abstract/MED/7923250

P A Ruffini

3

1 reference

Europe PubMed Central

12 July 2018

http://europepmc.org/abstract/MED/7923250

G Parmiani

5

1 reference

Europe PubMed Central

12 July 2018

http://europepmc.org/abstract/MED/7923250

G Broggi

6

1 reference

Europe PubMed Central

12 July 2018

http://europepmc.org/abstract/MED/7923250

A Salmaggi

7

1 reference

Europe PubMed Central

12 July 2018

http://europepmc.org/abstract/MED/7923250

publication date

1 September 1994

1 reference

Europe PubMed Central

12 July 2018

http://europepmc.org/abstract/MED/7923250

Cancer Immunology, Immunotherapy

1 reference

Europe PubMed Central

12 July 2018

http://europepmc.org/abstract/MED/7923250

39

1 reference

Europe PubMed Central

12 July 2018

http://europepmc.org/abstract/MED/7923250

3

1 reference

Europe PubMed Central

12 July 2018

http://europepmc.org/abstract/MED/7923250

193-197

1 reference

Europe PubMed Central

12 July 2018

http://europepmc.org/abstract/MED/7923250

Factors, including transforming growth factor beta, released in the glioblastoma residual cavity, impair activity of adherent lymphokine-activated killer cells.

1 reference

https://pubmed.ncbi.nlm.nih.gov/7923250

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Influence of PGE2- and cAMP-modulating agents on human glioblastoma cell killing by interleukin-2-activated lymphocytes

1 reference

https://pubmed.ncbi.nlm.nih.gov/7923250

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

T cell growth factor: parameters of production and a quantitative microassay for activity

1 reference

https://pubmed.ncbi.nlm.nih.gov/7923250

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lymphocytic infiltrates in primary glioblastomas and recidivous gliomas. Incidence, fate, and relevance to prognosis in 228 operated cases

1 reference

https://pubmed.ncbi.nlm.nih.gov/7923250

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Transforming growth factor-beta inhibits the in vitro generation of lymphokine-activated killer cells and cytotoxic T cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/7923250

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of LAK cells against three-dimensional tumor tissue. In vitro study using multi-cellular human glioma spheroids as targets.

1 reference

https://pubmed.ncbi.nlm.nih.gov/7923250

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibition of lymphocyte function by glioblastoma-derived transforming growth factor beta 2.

1 reference

https://pubmed.ncbi.nlm.nih.gov/7923250

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunobiology of primary intracranial tumors. Part 1: studies of the cellular and humoral general immune competence of brain-tumor patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/7923250

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II trial of Serratia marcescens extract in recurrent malignant astrocytoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/7923250

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Recurrent malignant gliomas: survival following interstitial brachytherapy with high-activity iodine-125 sources

1 reference

https://pubmed.ncbi.nlm.nih.gov/7923250

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Enhanced antimetastatic activity of lymphokine-activated killer cells purified and expanded by their adherence to plastic.

1 reference

https://pubmed.ncbi.nlm.nih.gov/7923250

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vitro generation and antitumor activity of adherent lymphokine-activated killer cells from the blood of patients with brain tumors.

1 reference

https://pubmed.ncbi.nlm.nih.gov/7923250

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells.

1 reference

https://pubmed.ncbi.nlm.nih.gov/7923250

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Neuro-oncology index and review (adult primary brain tumors). Radiotherapy, chemotherapy, immunotherapy, photodynamic therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/7923250

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sleep-promoting effects of endogenous pyrogen (interleukin-1).

1 reference

https://pubmed.ncbi.nlm.nih.gov/7923250

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunotherapy for malignant glioma using human recombinant interleukin-2 and activated autologous lymphocytes. A review of pre-clinical and clinical investigations

1 reference

https://pubmed.ncbi.nlm.nih.gov/7923250

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Development of multiple lesions during radiation therapy and chemotherapy in patients with gliomas.

1 reference

https://pubmed.ncbi.nlm.nih.gov/7923250

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A new approach to generating antitumor effectors for adoptive immunotherapy using human adherent lymphokine-activated killer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/7923250

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Preliminary trial of specific targeting therapy against malignant glioma

1 reference

https://pubmed.ncbi.nlm.nih.gov/7923250

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Regulation of lymphokine-activated killer activity and pore-forming protein gene expression in human peripheral blood CD8+ T lymphocytes. Inhibition by transforming growth factor-beta

1 reference

https://pubmed.ncbi.nlm.nih.gov/7923250

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of recurrent malignant glioma by repeated intracerebral injections of human recombinant interleukin-2 alone or in combination with systemic interferon-alpha. Results of a phase I clinical trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/7923250

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibition of tumor-specific cytotoxic T-lymphocyte responses by transforming growth factor beta 1

1 reference

https://pubmed.ncbi.nlm.nih.gov/7923250

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Glioblastoma multiforme: pathology, natural history and treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/7923250

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interleukin-2 or autologous lymphokine-activated killer cell treatment of malignant glioma: phase I trial.

1 reference

https://pubmed.ncbi.nlm.nih.gov/7923250

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Migration of recombinant IL-2-activated T and natural killer cells in the intercellular space of human H-2 glioma spheroids in vitro. A study on adhesion molecules involved

1 reference

https://pubmed.ncbi.nlm.nih.gov/7923250

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phenotype and functional activity of tumor-infiltrating lymphocytes isolated from immunogenic and nonimmunogenic rat brain tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/7923250

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Local administration of autologous lymphokine-activated killer cells and recombinant interleukin 2 to patients with malignant brain tumors.

1 reference

https://pubmed.ncbi.nlm.nih.gov/7923250

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S002620050113

1 reference

Europe PubMed Central

12 July 2018

http://europepmc.org/abstract/MED/7923250

1 reference

Europe PubMed Central

12 July 2018

http://europepmc.org/abstract/MED/7923250

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q55481786&oldid=1534864993"